CPIX

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Peers: CTOR SCYX SCLX DERM ASRT CRDL ANIK LFCR TKNO EBS

| Held by: VTI VXF DFAS DFMC IWC DFAT AVSC DFAC DFSU

Index	-
Market Cap	102.49M
Enterprise Value	101.22M
Income	-7.38M
Sales	41.94M
Book/sh	1.44
Cash/sh	0.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	93
IPO	Aug 11, 2009

P/E	-
Forward P/E	-
PEG	-
P/S	2.44
P/B	4.74
P/C	9.31
P/FCF	74.81
EV/EBITDA	-
EV/Sales	2.41
Quick Ratio	0.79
Current Ratio	0.95
Debt/Eq	0.47
LT Debt/Eq	0.44
Option/Short	Yes / Yes

EPS (ttm)	-0.49
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	20.68% 2.82%
Sales past 3/5Y	1.95% 3.52%
EPS Y/Y TTM	-106.57%
Sales Y/Y TTM	2.08%
EPS Q/Q	-366.87%
Sales Q/Q	-22.04%
Earnings	May 05 AMC
EPS/Sales Surpr.	- -

Insider Own	41.60%
Insider Trans	0.00%
Inst Own	18.43%
Inst Trans	-4.93%
ROA	-10.48%
ROE	-29.36%
ROIC	-23.65%
Gross Margin	72.42%
Oper. Margin	-16.75%
Profit Margin	-17.60%
SMA20	17.27%
SMA50	33.45%
SMA200	79.92%
Trades

Shs Outstand	14.98M
Shs Float	8.75M
Short Float	3.87%
Short Ratio	0.35
Short Interest	0.34M
52W High	6.75 1.33%
52W Low	1.85 269.73%
Volatility	7.02% 6.26%
ATR (14)	0.37
RSI (14)	73.36
Beta	0.08
Rel Volume	0.05
Avg Volume	968.25K
Volume	49,642

Perf Week	22.80%
Perf Month	14.38%
Perf Quarter	122.80%
Perf Half Y	62.86%
Perf YTD	71.86%
Perf Year	163.08%
Perf 3Y	356.00%
Perf 5Y	135.05%
Perf 10Y	52.00%
Recom	1.00
Target Price	9.75
Prev Close	6.75
Price	6.84
Change	1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-12	Reiterated	UBS	Neutral	$6.50 → $5
Feb-01-11	Reiterated	UBS	Neutral	$8 → $6.50
Dec-16-10	Downgrade	UBS	Buy → Neutral	$10 → $8
Aug-17-10	Reiterated	UBS	Buy	$11 → $10
Aug-17-10	Reiterated	Morgan Joseph	Buy	$15 → $10
Aug-17-10	Downgrade	Jefferies	Buy → Hold	$13 → $5.50
May-14-10	Reiterated	Morgan Joseph	Buy	$21 → $15

Jun-26-26 11:00AM	Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference (PR Newswire) +13.26%
Jun-02-26 09:05AM	Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis (PR Newswire)
May-28-26 09:05AM	CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV IN CHINA (PR Newswire)
May-06-26 08:30AM	Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary (Moby)
May-05-26 05:26PM	Cumberland: Q1 Earnings Snapshot (Associated Press)
05:00PM	Loading…
05:00PM	CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Apr-28-26 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Apr-24-26 06:14AM	Cumberland to sell drug portfolio to Apotex for $100m (Hospital Management)
Apr-23-26 10:52AM	Cumberland Pharmaceuticals jumps on $100M Apotex transaction (InvestorsHub) +27.87%
10:30AM	BC-Most Active Stocks (Associated Press)
09:00AM	Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex (PR Newswire)
Apr-22-26 08:00AM	RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 (PR Newswire)
Apr-16-26 09:05AM	CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE (PR Newswire)
Mar-17-26 09:05AM	Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting (PR Newswire)
Mar-10-26 01:49PM	Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales (Zacks) -7.33%
12:01AM	Loading…
Mar-04-26 12:01AM	Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -19.87%
Mar-03-26 06:02PM	Cumberland Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -5.37%
05:15PM	Cumberland: Q4 Earnings Snapshot (Associated Press Finance)
05:00PM	CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH (PR Newswire)
Feb-25-26 07:00AM	Joint U.S. Commercialization of RedHill's Talicia Commences (PR Newswire)
07:00AM	CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA (PR Newswire)
Feb-04-26 09:05AM	Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program (PR Newswire)
Jan-15-26 11:24AM	Niche Focus & Regulation Shape the Future of Healthcare Firms (Zacks)
Dec-23-25 04:00AM	Leading the charge the companies at the cutting edge of cell-based protein (Just Food)
Dec-19-25 05:02PM	Top Research Reports for NVIDIA, Netflix & Merck (Zacks)
08:53AM	Zacks Initiates Coverage of CPIX With Outperform Recommendation (Zacks)
Dec-08-25 09:05AM	CALDOLOR (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT (PR Newswire) -9.21%
Nov-05-25 12:02AM	Cumberland Pharmaceuticals Inc (CPIX) Q3 2025 Earnings Call Highlights: Strategic Product ... (GuruFocus.com) -12.41%
Nov-04-25 05:33PM	Cumberland: Q3 Earnings Snapshot (Associated Press Finance)
05:00PM	CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH (PR Newswire)
04:05PM	Loading…
Oct-28-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Oct-20-25 09:05AM	CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO (PR Newswire)
Oct-13-25 09:05AM	CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. (PR Newswire)
Oct-01-25 09:05AM	CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO (PR Newswire)
Sep-29-25 09:05AM	TABUK LAUNCHES VIBATIV FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA (PR Newswire)
Aug-06-25 03:25AM	Cumberland Pharmaceuticals Inc (CPIX) Q2 2025 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com) -15.30%
Aug-05-25 04:19PM	Cumberland: Q2 Earnings Snapshot (Associated Press Finance) -5.49%
04:05PM	Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date (PR Newswire)
Aug-04-25 09:05AM	CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV 4-VIAL STARTER PAK (PR Newswire) +13.92%
Jul-29-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Jun-23-25 09:05AM	Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference (PR Newswire) -9.66%
May-27-25 04:05PM	NEW STUDY FINDS CALDOLOR SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS (PR Newswire) +5.12% +9.36%
May-13-25 04:05PM	CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH (PR Newswire) +5.50% -10.79%
May-07-25 03:20AM	Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 04:05PM	Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 (PR Newswire)
Apr-29-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Mar-19-25 04:05PM	FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference (PR Newswire)
Mar-05-25 07:49AM	Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +11.90%
02:09AM	Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-04-25 04:50PM	Cumberland: Q4 Earnings Snapshot (Associated Press Finance) +17.70%
04:05PM	Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth (PR Newswire)
Feb-25-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS (PR Newswire) +6.57%
Feb-18-25 07:30AM	VIBATIV RECEIVES MARKETING APPROVAL IN CHINA (PR Newswire) -6.41%
Feb-05-25 05:23AM	Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD (Clinical Trials Arena) +35.11%
Feb-04-25 01:31PM	Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease (Benzinga) +76.53%
07:30AM	Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease (PR Newswire)
Dec-10-24 01:39PM	Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change (GuruFocus.com) +96.77%
12:08PM	Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? (Benzinga)
Dec-09-24 04:05PM	FDA APPROVES ACETADOTE sNDA (PR Newswire)
Nov-08-24 06:00PM	Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Nov-07-24 05:09PM	Cumberland: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update (PR Newswire)
Nov-06-24 05:21PM	CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (PR Newswire)
Nov-05-24 04:05PM	New Study Compares Caldolor (ibuprofen injection) to ketorolac (PR Newswire)
Oct-31-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS (PR Newswire) -5.88%
Aug-06-24 05:00PM	Cumberland: Q2 Earnings Snapshot (Associated Press Finance) +6.38%
04:05PM	Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 (PR Newswire)
Jul-30-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
May-13-24 08:50AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 06:15AM	Q1 2024 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.70%
May-07-24 08:58PM	CPIX Stock Earnings: Cumberland Reported Results for Q1 2024 (InvestorPlace)
05:06PM	Cumberland: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update (PR Newswire)
Apr-30-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS (PR Newswire) -5.60% -11.25%
Apr-02-24 04:05PM	NEW REPORT SUPPORTS USE OF CALDOLOR AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS (PR Newswire)
Mar-07-24 11:52AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript (Insider Monkey) +8.25%
Mar-06-24 06:55AM	Q4 2023 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 04:26PM	Cumberland: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Cumberland Pharmaceuticals Reports Annual 2023 Financial Results (PR Newswire)
Feb-27-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS (PR Newswire)
Nov-12-23 08:48AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:10PM	Cumberland: Q3 Earnings Snapshot (Associated Press Finance) -11.71%
04:05PM	Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS (PR Newswire) -10.10%
Oct-10-23 04:05PM	NEW VIBATV PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE (PR Newswire) -5.57% +7.69%
Aug-08-23 04:33PM	Cumberland: Q2 Earnings Snapshot (Associated Press Finance) +15.38%
04:05PM	Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 (PR Newswire)
Aug-01-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Jun-26-23 09:00AM	NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS (PR Newswire)
May-31-23 05:22AM	CPIX: A Solid Stock with an Exciting Catalyst (Zacks Small Cap Research)
May-23-23 09:00AM	CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (PR Newswire)
May-15-23 09:00AM	CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS (PR Newswire) +9.09%
May-09-23 05:29PM	Cumberland: Q1 Earnings Snapshot (AP Finance)
04:05PM	Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update (PR Newswire)
May-02-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Apr-17-23 09:52AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Screens Well But There Might Be A Catch (Simply Wall St.)
Mar-08-23 07:19AM	Q4 2022 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 04:22PM	CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 (PR Newswire)
Feb-28-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS (PR Newswire)
Nov-11-22 06:05AM	Cumberland Pharmaceuticals Third Quarter 2022 Earnings: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) (Simply Wall St.)

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

FounderMr. A. J. Kazimi MBA

Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.

VP of Trade & Distribution and Chief Compliance OfficerMr. James Lowrance Herman

Vice President of Sales & MarketingMr. Christopher T. Bitterman

Vice President of Organizational DevelopmentMr. Todd M. Anthony

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Cumberland Pharmaceuticals Inc

Upgrade your Finviz experience